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 The family of transforming growth factor beta (TGFβ)
molecules is a group of secreted polypeptides with functions
in cellular proliferation, differentiation and migration as well
as extracellular matrix metabolism [1]. Considerable evidence
has shown that TGFβ1 and 2 are potent profibrotic molecules
that have been implicated in numerous fibrotic diseases in-
cluding diabetic nephropathy, liver and pulmonary fibrosis,
rheumatoid arthritis, and more recently, ocular fibrotic dis-
eases [2].
Ocular pathologies associated with aberrant levels of ac-
tive TGFβ include cataracts, proliferative vitreoretinopathy
(PVR), as well as glaucoma [3-6]. The active form of TGFβ
has been detected in the ocular media from patients suffering
with cataracts [7,8] and in patients undergoing intraocular lens
implantation [9]. Moreover, patients treated with TGFβ2 to
treat retinal macular holes all developed cataracts after treat-
ment [10]. Two specific types of cataracts are associated with
elevated levels of activated TGFβ, including anterior subcap-
sular cataracts (ASC) and posterior capsular opacification
(PCO), also known as secondary cataract.
In ASC, focal opacities develop beneath the lens capsule
in the anterior region of the lens. These opacities or plaques
have been shown to be derived from an aberrant proliferation
of lens epithelial cells (LECs). A proportion of these cells also
undergo a transition into myofibroblasts, which express al-
pha-smooth muscle actin (αSMA), through a mechanism
known as epithelial to mesenchymal transformation (EMT)
[11]. As the cataracts further develop, the plaque cells secrete
extracellular matrix (ECM) components not found in the nor-
mal lens, such as collagen type I and IV, contributing to the
loss of lens transparency. PCO remains the major complica-
tion of modern cataract surgery with intraocular lens implan-
tation [12]. In PCO, the LECs which remain within the cap-
sule after cataract surgery are triggered to proliferate and mi-
grate to the posterior lens capsule [13] and like ASC, some of
these cells undergo a transition into myofibroblasts that se-
crete aberrant ECM.
Multiple in vitro and in vivo rodent models have been
developed for studying the mechanism(s) of TGFβ-induced
ASC. In vitro models include excised rat lenses, lens epithe-
lial explants and cell cultures that when exposed to TGFβ
undergo morphological changes similar to that seen in human
ASC including LEC transformation and inappropriate ECM
deposition [14-18]. Ectopic expression of active TGFβ1 in the
lens of transgenic mice under the transcriptional control of
the αA-crystallin [19] or βB-crystallin [20] promoter also re-
sults in ASC plaques that resemble those observed in humans.
More recently, two in vivo injury models for ASC have been
developed in mice including direct injury to the lens with a
hypodermic needle, as well as an alkali burn to the ocular sur-
face [21,22]. In both of these models LECs are stimulated to
undergo EMT through activation of TGFβ2. While the TGFβ
signaling intermediate, Smad3, was shown to be required for
the EMT observed in the lens injury model, in the alkali burn
model both EMT and ASC were shown to occur in the ab-
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sence of Smad3, albeit the effect was attenuated. Similarly,
our lab has shown that when the lens specific-TGFβ1
transgenic mice were bred onto the Smad3 knockout mouse
background, small ASC formed [23]. Thus, multiple models
have shown that alternative TGFβ signaling pathways partici-
pate in the development of ASC.
Our group has shown that transient overexpression of
bioactive TGFβ1 and β3 using adenoviral vectors results in
accumulation of parenchymal extracellular matrix and EMT
of epithelial cells, as demonstrated by increased expression of
αSMA in both the lung [24] and in the peritoneum [25]. More-
over, we have shown that adenoviral transfer of TGFβ1 pro-
duces transgene detectable by RNAse protection assay, ELISA
and a functional reporter assay, confirming transgene activity
[24,26,27]. We posited whether adenoviral transfer of TGFβ1
to the anterior segment of the rodent eye could be used to
induce EMT of LECs and create a novel model of ASC that
would not require injury or developmental expression of a
TGFβ transgene. Using adenoviral-LacZ (AdLacZ) we have
shown successful adenoviral transduction of a number of tis-
sues within the anterior segment of the eye, including the lens
epithelium. We further demonstrate that transfer of adenovi-
ral-(active) TGFβ1 (AdTGFβ1) to cells of the rodent anterior
segment resulted in the development of ASC plaques, within
4 days of injection, which continued to progress into large
fibrotic plaques by day 21. Finally, we employed this new
model to show that delivery of AdTGFβ1 to the anterior cham-
ber of genetically modified mice deficient in Smad3, results
in the formation of ASC plaques, confirming our earlier find-
ings that Smad3-independent signaling mechanisms partici-
pate in the EMT of LECs in ASC formation.
METHODS
Recombinant adenoviruses:  Full-length porcine TGFβ1 cDNA
was mutated at serines 223 and 225 (TGFβ1223/225) to render
the expressed protein product constitutively and biologically
active [28]. This mutated cDNA was used to construct a re-
combinant, replication-deficient type-5 adenovirus. The E1
region was replaced by the human cytomegalovirus promoter,
driving expression of TGFβ1223/225 followed by the SV40
polyadenylation signal [24]. The resulting replication-deficient
virus (AdTGFβ1) was amplified and purified by cesium chlo-
ride (CsCl) gradient centrifugation and concentrated using a
Sephadex PD-10 chromatography column, and finally plaque-
titered on 293 cells. The control vectors, AdDL, with no insert
in the deleted E1 region, or adenoviral vector expressing the
β-galactosidase gene (AdLacZ), coding for β-galactosidase,
or adenoviral vector expressing GFP (AdGFP), were produced
by similar methods [24,29].
Animal treatment:  All animals were treated in accordance
with the guidelines of the Canadian Council on Animal Care
and according to the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. Female, 6- to 8-week-
old C57BL/6 and FVB/n mice were purchased from Charles
River Laboratories (Montreal, PQ, Canada). Smad3 knockout
mice were generated by the removal of exon 8 of the Smad3
gene in mice of background 129SV/EV x C57BL/6 [30].
Smad3 heterozygous mice were bred under special pathogen-
free conditions. The genotypes of both wildtype (WT) and
Smad3 knockout (Smad3KO) mice were determined by PCR
analysis on tail DNA obtained from 3-wk-old animals. Tail
biopsies were digested overnight at 65 °C in buffer containing
0.1 M TrisHCl (pH 8.5), 5 mM EDTA (pH 8), 0.2% SDS, 200
mM NaCl and 0.2 mg/ml Proteinase K (Bioshop Canada,
Burlington, ON). Digested samples were spun down and su-
pernatants were mixed with 100% ethanol to precipitate ge-
nomic DNA, which was then diluted in 100 µl of sterile dis-
tilled water. Primer sequences were as follows: S3P1 5'-CCA
CTT CAT TGC CAT ATG CCC TG-3'; S3P2 5'-CCC GAA
CAG TTG GAT TCA CAC A-3'; S3P3 5'-CCA GAC TGC
CTT GGG AAA AGC-3'. The wild type allele was generated
using primers S3P1 and S3P2 giving a 400 bp fragment; the
knockout allele was generated using primers S3P1 and S3P3
giving a 250 bp fragment. PCR product was run on a 2% TAE
agarose gel and visualized by ethidium bromide staining un-
der UV light. All experiments were performed with littermates
to rule out any background effects. All animals were housed
under specific pathogen free conditions and rodent laboratory
food and water were provided ad libitum. All animal proce-
dures were performed under inhalation anesthesia with
isofluorane (MTC Pharmaceuticals, Cambridge, ON, Canada).
AdTGFβ1 or AdDL or AdLacZ (5x108 pfu) were adminis-
tered in a volume of 5 µl phosphate-buffered saline (PBS).
Briefly, mice were anesthetized with isofluorane and placed
under a dissecting microscope, in order to visualize general
eye structures. A volume of no more than 5 µl of virus solu-
tion was injected into the anterior chamber using a 33 gauge
needle affixed to a 10 µl Hamilton syringe. Eyes were cov-
ered with Lacri-lube® after injection and animals were al-
lowed to recover before returning to their cages. Animals were
sacrificed and enucleated 4 or 21 days after injection.
Histology:  After fixation in 10% buffered formalin for
48 h, tissues were embedded in paraffin by routine methods.
Three-micrometer thick midsagittal sections were cut and
stained with hematoxylin and eosin to visualize general tissue
architecture. Additional sections were stained with Masson’s
trichrome and periodic acid Schiff (PAS) to demonstrate ECM
components. Immunohistochemistry using an antibody against
α-smooth muscle actin (αSMA, clone 1A4; DakoCytomation,
Mississauga, ON) was used to localize contractile elements.
The brown color reaction was performed with the Animal
Research Kit (DakoCytomation, Mississauga, ON). Studies
to fluorescently colocalize αSMA employed a monoclonal
antibody conjugated to FITC (clone 1A4; Sigma-Aldrich,
Oakville, ON). In addition, sections were stained with
polyclonal antibodies to β- and γ-crystallin (kindly provided
by Dr. J.S. Zigler, National Eye Institute, Bethesda, MD), col-
lagen IV (Cedarlane Laboratories, Hornby, ON), PCNA, and
TGFβ1 (Santa Cruz Biotechnologies, Santa Cruz, CA). Sec-
ondary antibodies included goat anti-rabbit rhodamine and goat
anti-rabbit FITC (Bioshop Canada, Burlington, ON). TUNEL
staining was carried out using the ApopTag® Fluoescein In
Situ Apoptosis Detection Kit according to the manufacturer’s
instructions (Millipore, Temecula, CA).
458LacZ staining and GFP visualization:  All reagents were
purchased from Bioshop Canada (Burlington, ON). Directly
after enucleation, eyes were placed whole in fixative buffer
containing 0.2% glutaraldehyde, 5 mM EGTA pH 7.3, 2 mM
MgCl2 in 0.1 M sodium phosphate buffer pH 7.3 for 30 min.
They were then washed three times of 5 min each with wash
buffer containing 2 mM MgCL2, 0.01% deoxycholate, 0.02%
Nonidet P-40 in 0.1 M sodium phosphate buffer, pH 7.3. Stain-
ing was carried out overnight at 37 °C in staining buffer con-
taining 2.0 ml of 25 mg/ml X-gal, 0.106 g potassium ferro-
cyanide and 0.082 g potassium ferricyanide in 50 ml of wash
buffer. After staining, tissues were washed three times of 5
min each and placed in 10% neutral buffered formalin for an
additional 24 h to ensure adequate fixation prior to section-
ing. Three micrometer thick midsagittal sections were cut and
counterstained with nuclear fast red using routine methods.
Frozen sections from eyes treated with AdGFP were kept
at -20 °C until use. Sections were then allowed to come to
room temperature, washed three times for 5 min with PBS
and coverslipped with Vectashield® mounting medium with
DAPI (Vector Laboratories, Burlinghame, CA).
RESULTS
Anterior structures of the eye can be transduced with aden-
ovirus four days post injection:  To determine the cell and
tissue types in the anterior chamber of the eye that can be
infected with adenovirus, we injected reporter constructs,
AdLacZ (5x108 pfu or 1x109 pfu) or AdGFP (5x108 pfu or
1x109 pfu) intracamerally into mice of a C57BL/6 or FVB/n
background, respectively. LacZ staining was then performed
to localize transgene expression. Grossly, LacZ positive eyes
could be distinguished from eyes injected with control virus
containing no transgene (AdDL) simply by the bluish corneal
opacity (Figure 1A) in contrast to the clear corneas of the
AdDL-treated mice. Histological midsagittal sections of
AdLacZ treated eyes revealed that after 4 days, LacZ staining
was observed in multiple structures of the anterior chamber,
including the corneal endothelium, iris, ciliary body and tra-
becular meshwork (Figure 1B). Transgene was also detect-
able in the lens epithelium (Figure 1C) in absence of capsular
break, but typically at the higher dose (1x109 pfu). Animals
injected with the AdDL vector (Figure 1D) did not show any
LacZ staining. Transduction of lens epithelial cells was also
©2007 Molecular Vision Molecular Vision 2007; 13:457-69 <http://www.molvis.org/molvis/v13/a48/>
Figure 1. Expression of adenovirally transferred LacZ and GFP.  Animals were injected with AdLacZ (A-C), AdDL (D), or AdGFP (E)
intracamerally. Four days post injection eyes were removed and wholemount stained for LacZ activity (A) followed by paraffin sectioning
(B,C,D) or frozen sectioning and visualized using a GFP filter (E). Blue corneal opacity (asterisks in A) indicates that cellular infection and
production of transgene was successful. AdDL eyes remained clear (hash marks in A). B and C demonstrate transgene expression in the
corneal endothelium (En), iris (Ir), ciliary body (Cb), trabecular meshwork (Tm), and lens epithelium (Ep). Transgene was absent in control
vector treated eyes (D). Transgene expression is confirmed in the lens epithelium (Ep) using AdGFP (green). The scale bars in A = 1 mm, in B-
D = 25 µm, and in E = 50 µm.
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Figure 2. Effects of adenoviral gene transfer of active TGFβ1 after four days.  Histological sections from C57 mice injected with AdTGFβ1 (A
and B) or AdDL (C and D). Sections were stained with H&E (A and C) or subjected to immunostaining for αSMA (B and D). Focal multilayering
occurs in animals treated with AdTGFβ and is associated with induction of αSMA (A, B) in contrast to AdDL treated eyes (C, D). The green
stain is αSMA and the blue stain is DAPI. The scale bar is equal to 25 µm.
confirmed by expression of GFP (Figure 1E) after intracameral
injection with AdGFP. In comparison to 4 days post-injection,
21 days after injection with AdLacZ, only faint LacZ staining
was observed in the trabecular meshwork and corneal endot-
helium and none was observed in the lens (data not shown).
Gene transfer of active TGFβ1 to the anterior chamber
induces ASC formation:  One eye of each mouse (6-8 weeks
old; C57BL) was injected with AdTGFβ1 or AdDL. Four days
post injection, 13 lenses out of 15 eyes treated with AdTGFβ1
(Figure 2A) showed distinct ASC plaques consisting of a fo-
cal multilayering of LECs beneath the intact anterior lens cap-
sule. Each of the AdTGFβ1-treated eyes commonly exhibited
one plaque, typically found in a central location of the ante-
rior region of the lens. In comparison to those treated with
AdTGFβ1, 2 lenses out of 15 eyes injected with AdDL exhib-
ited subcapsular plaques in the absence of any lens rupture.
However, these eyes also showed a moderate amount of in-
flammation, suggesting that the cataracts may have developed
in response to excessive injury in the anterior segment of the
eye. The remaining 13 eyes, showed a normal, lens epithelial
monolayer (Figure 2C). Injection with either AdTGFβ1 or
AdDL also produced a mild inflammatory response as evi-
denced by presence of a small number of neutrophils and
macrophages both in the aqueous humor and within the cor-
neal stroma. These effects were transient and absent by day
21. AdTGFβ1 treated eyes, however, demonstrated persistent
thickening and increased cellularity of the corneal stroma, as
well as a reduction in the number of corneal epithelial layers.
Adhesions between the corneal endothelium and iris were also
common. These non-lens features have also been reported in
the TGFβ1-transgenic mouse models, whereby active TGFβ1
is overexpressed in lens fiber cells during embryogenesis
[19,20]. These shared features are likely a result of TGFβ
overexpression and not due to adenoviral infection. Impor-
tantly, AdDL animals did not show these features at any time-
point examined and the contralateral/uninjected eyes remained
normal during the entire course of the study (data not shown).
To  determine whether plaques consisted of
myofibroblasts, as previously reported in human ASC and
animal models of ASC, sections of the day 4 AdTGFβ1- and
AdDL-treated eyes were subjected to immunohistochemical
staining for αSMA. In AdTGFβ1-treated eyes, distinct expres-
sion of αSMA was observed in a proportion of the cells in the
plaques of the lenses which exhibited subcapsular plaques
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Figure 3. Immunolocalization of TGFβ1.  Naïve (A), AdDL injected (B), and AdTGFβ1 injected eyes (C and D) were sectioned and subjected
to TGFβ1 immunohistochemistry at 0 (A), 4 (B and C) and 21 (D) days after injection. Both naïve and AdDL eyes show no immunolocalization
of TGFβ1 in the lens epithelium. Animals injected with AdTGFβ1 demonstrate prominent expression of TGFβ1 in the lens epithelium. The
green stain is TGFβ1 and the blue stain is DAPI. The scale bar is equal to 25 µm.
(Figure 2B). Expression was also observed in some of the ad-
jacent monolayer of cells in the anterior lens region. How-
ever, the monolayer lens epithelium distal to the site in
AdTGFβ1-treated eyes did not express αSMA. In compari-
son, AdDL treated eyes, showed no detectable expression of
αSMA in the lens (Figure 2D).
To determine if injection with AdTGFβ1 resulted in
overexpression of TGFβ1 in the lens, we performed immuno-
histochemistry on paraffin sections from naïve, AdTGFβ1 and
AdDL treated eyes. Naïve lenses (Figure 3A) and those of
AdDL (Figure 3B) did not show any TGFβ1 expression. How-
ever, animals treated with AdTGFβ1 showed positive expres-
sion of TGFβ1 in the lens plaques and adjacent lens epithe-
lium at both days 4 (Figure 3C) and 21 (Figure 3D). Addition-
ally, treatment with AdTGFβ1 resulted in strong expression
of TGFβ1 protein in the corneal epithelium, stroma, and en-
dothelium. Naïve and AdDL animals showed only faint ex-
pression limited to the cornified layer of the corneal epithe-
lium and corneal endothelium and no expression in the stroma
(data not shown).
To determine if the effects of AdTGFβ1 delivery to the
anterior chamber were transient or chronic, we examined lenses
of treated animals at 21 days post injection. Plaques seen in
AdTGFβ1 treated eyes showed a marked increase in plaque
size (Figure 4A). A proportion of these cells exhibited posi-
tive αSMA (Figure 4B) expression. AdDL treated eyes again
showed no change in histological architecture (Figure 4C),
lacked αSMA immunoreactivity (Figure 4D), and were strik-
ingly similar to untreated lenses (data not shown).
AdTGFβ1 induces expression of markers associated with
fiber cell differentiation:  As shown above, not all of the cells
in the plaques expressed αSMA. In order to clarify the nature
of the cellular heterogeneity found in AdTGFβ1 induced ASC,
we examined crystallin expression. It has been shown previ-
ously that LECs which do not express αSMA, expressed β-
crystallin, an early fiber cell marker [31]. We therefore exam-
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Figure 4. Effects of adenoviral
gene transfer of active TGFβ1
after twenty one days..  Histo-
logical sections from C57 mice
injected with AdTGFβ1 (A and
B) or AdDL (C and D). Sec-
tions were stained with H&E
(A and C) or subjected to
immunostaining for αSMA (B
and D). At 21 days post injec-
tion AdTGFβ1 treated eyes
demonstrate large plaques
which express a considerable
amount of αSMA in contrast
to AdDL treated eyes. The
green stain is αSMA and the
blue stain is DAPI. The scale
bar is equal to 25 µm.
ined expression of β-crystallin in the subcapsular plaques of
the AdTGFβ1 lenses at 4 and 21 days post injection. We ob-
served detectable β-crystallin staining in a subpopulation of
cells in the plaques of AdTGFβ1-treated eyes at both 4 (Fig-
ure 5A) and 21 days (Figure 5C) but no such detection in the
epithelial monolayer of AdDL treated eyes at both time points
(Figure 5B,D, respectively). Moreover, we were also able to
detect expression of γ-crystallin in a subpopulation of cells in
the plaques of AdTGFβ1 (Figure 5E) but not in the epithelial
monolayer of AdDL (Figure 5F) lenses at 21 days.
AdTGFβ1 induces aberrant expression of ECM compo-
nents:  Inappropriate deposition of ECM is a characteristic
feature of human ASC, and is also well documented in the
transgenic mouse ASC model. We therefore examined the
matrix composition of the ASC plaques in mice injected with
AdTGFβ1 at both 4 and 21 days. To do so we employed the
use of routine PAS histochemistry to detect carbohydrate depo-
sition as well as Masson’s trichrome to detect collagen depo-
sition. Since both of these stains highlight the lens capsule in
normal untreated lenses, we used this as an internal, positive
control. At day 4 post-injection with AdTGFβ1 (Figure 6A,E)
the subcapsular plaques demonstrated detectable amounts of
matrix deposition in contrast to treatment with AdDL (Figure
6B,F). However, at 21 days post injection, the ASC plaques in
the AdTGFβ1-treated eyes exhibited notable deposits of both
carbohydrate (Figure 6C) and collagen (Figure 6G). AdDL
treated animals showed no matrix accumulation at this time
(Figure 6D,H).
Collagen IV is the most abundant collagen found in the
lens capsule but is absent in the lens epithelium. We therefore
used immunohistochemistry to reveal whether collagen type
IV was aberrantly expressed in the epithelial cells comprising
the plaque. Animals treated with AdTGFβ1 showed collagen
IV accumulation at both days 4 and 21 (Figure 7A,C, respec-
tively) whereas those animals treated with AdDL showed no
accumulation at either time point (Figure 7B,D).
AdTGFβ1 induces ASC in Smad3-knockout mice:  With
our findings that AdTGFβ1 delivery to the anterior chamber
resulted in the development of ASC reminiscent of that ob-
served in other animal models and human ASC, we next em-
ployed this model to further confirm our earlier findings [23]
that ASC can develop in the absence of the Smad3 signaling
intermediate. We tested this by delivering AdTGFβ1 to the
anterior chamber of Smad3KO eyes. Four days post injection
of AdTGFβ1, the lenses of Smad3KO and WT mice showed
distinct subcapsular plaques consisting of a focal multi-layer-
ing of cells in the central, anterior region (Figure 8A,B, re-
spectively) that were positive for αSMA expression (Figure
8C,D, respectively). However, Smad3KO mice exhibited
plaques that were reduced in size relative to those seen in WT
littermates. To further investigate why the plaques in the
Smad3KO mice were smaller than WT littermates we per-
formed experiments to assess both cellular proliferation and
apoptosis. To detect cellular proliferation, we immunostained
sections with proliferating cell nuclear antigen (PCNA). These
experiments showed no observable difference in the amount
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Figure 5. Crystallin expression in AdTGFβ1 treated eyes..  Sections were stained with anti-β (A-D; red) or anti-γ-crystallin (E and F; green)
antibodies and counterstained with DAPI (blue). Additionally, β-crystallin stained sections were colocalized with αSMA (A-D; green). Sec-
tions were taken at four days (A and B) and at twenty one days (C-F) of both AdTGFβ1 (A, C, and E) and AdDL (B, D, and F). Both β- and
γ-crystallin expression can be seen with in the plaques of AdTGFβ1 but not AdDL treated eyes. Epithelia of AdDL treated eyes showed no
presence of crystallin or αSMA expression. The scale bar is equal to 25 µm.
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Figure 6. Matrix staining of AdTGFβ injected eyes..  Sections of AdTGFβ1 (A, C, E, and G) and AdDL (B, D, F, and H) lenses taken on days
4 (A, B, E, and F) and 21 (C, D, G, and H) were stained with PAS (A-D) to detect carbohydrates (purple) and Masson’s trichrome (E-H) to
detect collagens (green). AdTGFβ1 treated lenses showed accumulation of matrix which was barely detectable on day 4, but prominent on day
21. In contrast, AdDL treated lenses showed no matrix accumulation at any time point. The scale bar is equal to 25 µm.
464of cells immunoreactive to PCNA in the lens plaques of
AdTGFβ1-treated Smad3KO mice (Figure 8E) versus plaques
in the AdTGFβ1-treated WT littermates (Figure 8F). How-
ever, TUNEL staining, used to detect apoptotic cells, revealed
that plaques from the AdTGFβ1-treated Smad3KO mice had
substantially more apoptotic cells than plaques of the
AdTGFβ1-treated wild-type littermates (Figure 8G,H, respec-
tively).
DISCUSSION
 In this study we have developed a novel model for ASC. Ad-
enoviral delivery of TGFβ1 to the anterior chamber of the
mouse eye produced the formation of distinct subcapsular cata-
racts, 4 days post injection, which exhibited features of ASC
plaques described in humans and other rodent models, includ-
ing an induction in αSMA expression and aberrant deposition
of ECM. Unlike TGFβ1-transgenic mouse models, whereby
active TGFβ1 is overexpressed in lens fiber cells during em-
bryogenesis [19,20], the AdTGFβ1 gene delivery model does
not require the postnatal period (21 days after birth) that the
transgenic models require for subcapsular plaques to be ob-
served. Also, since heterozygote lines of the transgenic mice
are typically used for examination, due to the severity of the
homozygous phenotype, each mouse or embryo of the TGFβ1-
transgenic line to be examined must be genotyped. The
AdTGFβ1 model does not require crossbreeding or genotyping
and can therefore be more easily employed in studies utilizing
genetically modified mice.
Intravitreal injection of recombinant TGFβ into the rat
eye [32] has been shown to produce ASC following 15 weeks
post injection, however the ASC were not well defined and
were accompanied by a number of other lens defects, includ-
ing cortical clouding, disrupted bow region, nucleated fiber
cells, vacuolation of fiber cells, and posterior subcapsular cata-
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Figure 7. Collagen IV expression..  Immunolocalization of collagen IV was performed on paraffin sections of AdTGFβ1 (A and C) and AdDL
(B and D) lenses on days 4 (A and B) and 21 (C and D). AdTGFβ1 treated eyes showed a marked accumulation of collagen IV in the plaques
which was absent in epithelia of AdDL treated eyes. The red staining is collagen IV and the blue staining is DAPI. The scale bar is equal to 25
µm.
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Figure 8. Effects of adenoviral gene transfer of active TGFβ1 to Smad3KO eyes after four days..  Histological sections from Smad3KO (A, C,
E, and G) and WT (B, D, F, and H) treated with AdTGFβ1. Both groups developed αSMA (brown; C and D) expressing plaques, and showed
no difference in cellular proliferation by the PCNA (green) stain (E and F). Smad3 KO (G) animals demonstrated more TUNEL (green)
positive cells (arrows) compared to WT (H). The scale bar is equal to 25 µm.
466racts containing swollen and degenerating cells. These fea-
tures are not typically found in patients with ASC and none of
these features were observed in our AdTGFβ model, even at 3
weeks post injection. Injection into the vitreous cavity as op-
posed to the anterior chamber may have different outcomes.
For example, Oksala et al. [33] found that intracameral injec-
tion of calcitonin gene-related peptide (CGRP) increased,
whereas intravitreal injection of CGRP decreased intraocular
pressure. Thus, the difference in response to TGFβ in the two
models may be related to the site of delivery. Intracameral
delivery of recombinant TGFβ in rodents has not been de-
scribed, and this may be due to the fact that it is quickly turned
over in the anterior chamber through drainage of the aqueous
humor [34].
Another in vivo model of ASC is a lens injury model in
mice [35]. In this model, a hypodermic needle is inserted trans-
corneally to disrupt the lens capsule, resulting in the EMT of
LECs and ASC formation. While this model produces many
of the features observed in human ASC, one aspect of this
model is rupture of the lens capsule, which is not associated
with ASC development. Disruption of the capsule in the lens
injury model results in exposure of the lens crystallins to resi-
dent antigen presenting cells and may elicit an immune re-
sponse that may not normally be found in ASC patients [36,37].
Similarly, the recent ASC model developed using topical al-
kali application to the ocular surface elicits wound responses
in multiple tissues of the anterior segment [22]. Use of aden-
oviral vectors in vivo [38] typically induces both innate and
adaptive immune responses to the viral proteins [39]. Ante-
rior chamber injections, however, typically do not produce
systemic responses and do not induce delayed type hypersen-
sitivity when animals are re-challenged with antigen [40]. Thus,
in the AdTGFβ1 model, the lens capsule remains intact and
only a minimal immune response directed against the aden-
oviral vector is observed. Additionally, since transgene ex-
pression is transient, a small initial dose may be all that is
required [41].
While many laboratories have shown that adenovirus can
transduce lens epithelial cells in culture [42], the ability of the
adenovirus to transduce the lens epithelium in vivo has been a
matter of debate [43]. However, using both AdGFP and
AdLacZ vectors we demonstrated that adenoviral delivery to
the anterior chamber resulted in transduction of the mouse
lens epithelium, in the absence of a capsular break. Addition-
ally, AdTGFβ1 treated eyes showed upregulated levels of
TGFβ1 in the lens epithelium. Recent work has shown that
intravitreal injection of AAV vectors encoding enhanced green
fluorescent protein can also transduce the lens epithelium [44].
In addition to the lens, we found that multiple structures of
the anterior chamber, including the corneal endothelium and
stromal cells, were also transduced by AdLacZ. Thus, deliv-
ery of the AdTGFβ1 may have resulted in the transduction of
many of these tissues which as a result may have contributed
to development of the AdTGFβ1-induced ASC. At the present
time it is not known whether transduction of the lens is re-
quired for development of ASC. Nonetheless, the intracameral
delivery of AdTGFβ1 represents a quick and reproducible
model for ASC in mice.
Employment of the AdTGFβ1 model to the Smad3 defi-
cient mice confirmed our earlier findings demonstrating that
while Smad3 is sufficient for, it is not necessary for the EMT
of LECs during ASC formation in vivo. In our recent study,
TGFβ1 transgenic mice expressing active TGFβ1 under the
αA-crystallin promoter, were bred onto a Smad3KO back-
ground and exhibited ASC plaques, albeit they were smaller
than those found in their wild-type littermates [23]. This was
correlated with an increase in apoptosis in the subcapsular
plaques and a decrease in expression of collagen type IV. Simi-
lar to these findings, we also observe that AdTGFβ1 induced
ASC were smaller in Smad3KO animals compared to their
wildtype littermates and exhibited higher numbers of apoptotic
cells. We further extended this finding to show that prolifera-
tion of cells in the ASC, as assessed by PCNA immunostaining,
did not appear to differ between the AdTGFβ1-treated
Smad3KO and wild-type mice. Thus together these data sug-
gest that decreased cell survival is likely to be the underlying
cause of the smaller sized plaques in the Smad3KO mice.
Findings for the models described above, as well as the
recently developed alkali burn model, are in contrast to ear-
lier work by Saika and colleagues which showed that Smad3
deficient mice were resistant to ASC formation in response to
lens injury [45]. One possible explanation for the difference,
as also pointed out by these authors [22], is that the levels of
active TGFβ produced in each of the models may be different.
The adenoviral gene transfer and transgenic approaches may
have produced larger amounts of active TGFβ than that of the
lens injury model. Indeed different transgenic promoters with
different strengths were shown to result in variability in the
severity of anterior chamber and lens defects in mice [19,20].
Finally, individual susceptibility among mouse strains has been
well documented and may explain some of these differences.
For example, strains that are susceptible to fibrosis-inducing
stimuli include C57BL/6, which were used in these studies
[46-50].
In summary, we have developed a novel model of ASC
involving adenoviral delivery of active porcine TGFβ1 to the
anterior segment of rodent eye. AdTGFβ1 induced ASC con-
sisting of epithelial multilayering beneath the lens capsule and
induction of αSMA expression within 4 days, which was suf-
ficient to further induce aberrant deposition of ECM in mice
out to 21 days post infection. We also confirm that TGFβ1-
induced EMT of LECs as evidenced by αSMA expression is
not Smad3-dependent in that Smad3 deficient mice can de-
velop small ASC plaques that are αSMA positive, further dem-
onstrating that additional TGFβ signaling cascades participate
in the EMT of LECs and ASC formation.
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